RS56701B1 - Fuzionisana triciklična heterociklična jedinjenja kao inhibitori hiv integraze - Google Patents

Fuzionisana triciklična heterociklična jedinjenja kao inhibitori hiv integraze

Info

Publication number
RS56701B1
RS56701B1 RS20180010A RSP20180010A RS56701B1 RS 56701 B1 RS56701 B1 RS 56701B1 RS 20180010 A RS20180010 A RS 20180010A RS P20180010 A RSP20180010 A RS P20180010A RS 56701 B1 RS56701 B1 RS 56701B1
Authority
RS
Serbia
Prior art keywords
heterocyclic compounds
hiv integrase
integrase inhibitors
tricyclic heterocyclic
fused tricyclic
Prior art date
Application number
RS20180010A
Other languages
English (en)
Inventor
Paul J Coleman
Timothy J Hartingh
Izzat T Raheem
John Schreier
John T Sisko
John Wai
Thomas Graham
Lihong Hu
Xuanjia Peng
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of RS56701B1 publication Critical patent/RS56701B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
RS20180010A 2013-05-17 2014-04-18 Fuzionisana triciklična heterociklična jedinjenja kao inhibitori hiv integraze RS56701B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361824739P 2013-05-17 2013-05-17
EP14798188.0A EP2997033B1 (en) 2013-05-17 2014-04-18 Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
PCT/CN2014/075685 WO2014183532A1 (en) 2013-05-17 2014-04-18 Fused tricyclic heterocyclic compounds as hiv integrase inhibitors

Publications (1)

Publication Number Publication Date
RS56701B1 true RS56701B1 (sr) 2018-03-30

Family

ID=51897679

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180010A RS56701B1 (sr) 2013-05-17 2014-04-18 Fuzionisana triciklična heterociklična jedinjenja kao inhibitori hiv integraze

Country Status (19)

Country Link
US (1) US9643982B2 (sr)
EP (2) EP3330272B1 (sr)
AR (1) AR096332A1 (sr)
AU (1) AU2014267951A1 (sr)
CY (1) CY1119842T1 (sr)
DK (1) DK2997033T3 (sr)
ES (1) ES2656696T3 (sr)
HK (1) HK1248685A1 (sr)
HR (1) HRP20180081T1 (sr)
HU (1) HUE036384T2 (sr)
LT (1) LT2997033T (sr)
ME (1) ME02977B (sr)
NO (1) NO3058793T3 (sr)
PL (1) PL2997033T3 (sr)
PT (1) PT2997033T (sr)
RS (1) RS56701B1 (sr)
SI (1) SI2997033T1 (sr)
TW (1) TWI656122B (sr)
WO (1) WO2014183532A1 (sr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3757105B1 (en) 2014-08-22 2024-07-24 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
TWI520963B (zh) * 2014-12-24 2016-02-11 國立清華大學 １，９－二氮萉衍生物及其製法
WO2017113288A1 (en) * 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
BR112019011074B1 (pt) * 2016-12-02 2021-01-19 Merck Sharp & Dohme Corp. Compostos heterocíclicos tricíclicos inibidores de hiv integrase, composição que oscompreende e uso dos mesmos
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
CA3101180A1 (en) * 2018-04-27 2019-10-31 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
AR115455A1 (es) 2018-05-31 2021-01-20 Shionogi & Co Derivado de piridotriazina policíclica
SG11202011386QA (en) 2018-05-31 2020-12-30 Shionogi & Co Polycyclic pyridone derivative
EP3801543B1 (en) 2018-06-05 2024-09-11 Merck Sharp & Dohme LLC Tricyclic heterocycle compounds useful as hiv integrase inhibitors
HUE064542T2 (hu) 2018-06-21 2024-03-28 Hoffmann La Roche A 3-((1R,3R)1(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9 -tetrahidro-2H-pirido[3,4-b]indol-2-il)-2,2-difluoropropán-1-ol tartarátsó szilárd formái, eljárás elõállításukra és rákos megbetegedések kezelésében történõ alkalmazási módszereik
TWI745900B (zh) 2019-03-22 2021-11-11 美商基利科學股份有限公司 橋鍵聯三環胺甲醯吡啶酮化合物及其醫藥用途
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
WO2021107066A1 (ja) 2019-11-28 2021-06-03 塩野義製薬株式会社 インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬
PE20221569A1 (es) * 2020-02-24 2022-10-06 Gilead Sciences Inc Compuestos tetraciclicos para el tratamiento de infecciones por vih
ES2968058T3 (es) 2021-01-19 2024-05-07 Gilead Sciences Inc Compuestos de piridotriazina sustituidos y usos de los mismos
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3042894A1 (en) 2001-08-10 2016-07-13 Shionogi & Co., Ltd. Antiviral agent
AU2002334205B2 (en) 2001-10-26 2007-07-05 Istituto Di Ricerche Di Biologia Molecolara P. Angeletti Spa Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
SI1441735T1 (sl) 2001-10-26 2006-06-30 Angeletti P Ist Richerche Bio N-substituirani hidroksipirimidinon-karboksamidniinhibitorji HIV-integraze
DE60315796T2 (de) 2002-01-17 2008-06-05 Merck & Co., Inc. Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen
EP1578748B1 (en) 2002-12-27 2010-09-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
WO2004062613A2 (en) 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7037908B2 (en) 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
AR046938A1 (es) 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
WO2005086700A2 (en) * 2004-03-09 2005-09-22 Merck & Co., Inc. Hiv integrase inhibitors
CA2557926A1 (en) * 2004-03-09 2005-09-22 Monica Donghi Hiv integrase inhibitors
WO2005092099A1 (en) 2004-03-09 2005-10-06 Merck & Co., Inc. Hiv integrase inhibitors
AU2005222391B2 (en) 2004-03-09 2010-11-11 Merck Sharp & Dohme Corp. HIV integrase inhibitors
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
US7157447B2 (en) 2004-05-28 2007-01-02 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7173022B2 (en) 2004-05-28 2007-02-06 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7192948B2 (en) 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
CA2600832C (en) 2005-03-31 2011-12-13 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hiv integrase inhibitors
US7494984B2 (en) 2005-08-31 2009-02-24 Bristol-Myers Squibb Company Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
WO2007059125A2 (en) 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7902182B2 (en) 2005-11-16 2011-03-08 Bristol-Myers Squibb Company HIV integrase inhibitors
US8039458B2 (en) 2005-11-17 2011-10-18 Bristol-Myers Squibb Company HIV integrase inhibitors
US7897593B2 (en) 2006-05-30 2011-03-01 Bristol-Myers Squibb Company HIV integrase inhibitors
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2011045330A1 (en) 2009-10-13 2011-04-21 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
NZ601847A (en) * 2010-02-26 2014-03-28 Japan Tobacco Inc 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
RU2567385C2 (ru) 2010-04-02 2015-11-10 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Макроциклические ингибиторы интегразы

Also Published As

Publication number Publication date
EP3330272A1 (en) 2018-06-06
TW201524978A (zh) 2015-07-01
AU2014267951A1 (en) 2015-11-19
PT2997033T (pt) 2018-01-25
ES2656696T3 (es) 2018-02-28
TWI656122B (zh) 2019-04-11
HRP20180081T1 (hr) 2018-02-23
US9643982B2 (en) 2017-05-09
HUE036384T2 (hu) 2018-07-30
AR096332A1 (es) 2015-12-23
ME02977B (me) 2018-10-20
PL2997033T3 (pl) 2018-04-30
LT2997033T (lt) 2018-02-12
CY1119842T1 (el) 2018-06-27
NO3058793T3 (sr) 2018-03-17
EP2997033A1 (en) 2016-03-23
EP3330272B1 (en) 2021-02-17
HK1248685A1 (zh) 2018-10-19
SI2997033T1 (en) 2018-04-30
EP2997033B1 (en) 2017-11-15
WO2014183532A1 (en) 2014-11-20
EP2997033A4 (en) 2016-10-26
DK2997033T3 (da) 2018-01-29
US20160108059A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
HK1248685A1 (zh) 作為hiv整合酶抑制劑的稠合三環雜環化合物
EP3008044A4 (en) Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
HK1221648A1 (zh) 用作 整合酶抑制劑的取代喹嗪衍生物
HK1210166A1 (en) Fused tricyclic amide compounds as multiple kinase inhibitors
EP2862853A4 (en) FUSED HETEROCYCLIC COMPOUND
EP2865671A4 (en) CONDENSED HETEROCYCLIC COMPOUND
EP2857396A4 (en) CONDENSED HETEROCYCLIC COMPOUND
EP2857397A4 (en) CONDENSED HETEROCYCLIC COMPOUND
EP2931730A4 (en) 4-PYRIDINONETRIAZINE DERIVATIVES AS INHIBITORS OF HIV INTEGRASE
EP2982666A4 (en) HETEROCYCLIC COMPOUND
HK1221465A1 (zh) 新型雜環化合物
HK1217492A1 (zh) 作爲刺猬信號通路抑制劑的雜環化合物
IL245379A0 (en) Heterocyclic n-acylamino compounds
EP2865672A4 (en) FUSED HETEROCYCLIC COMPOUND
EP3018126A4 (en) HETEROCYCLIC COMPOUND
IL254424A0 (en) Disubstituted heterocyclic tricyclic compounds
EP2877469A4 (en) SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS INHIBITORS OF HIV INTEGRASE
EP2980089A4 (en) HETEROCYCLIC CONNECTION
HRP20190133T1 (hr) Heterociklički spoj
EP2982670A4 (en) HETEROCYCLIC COMPOUND
IL244347A0 (en) n-acylamino heterocyclic compounds
GB201314960D0 (en) Heterocyclic derivatives
GB201300306D0 (en) Heterocyclic derivatives